17 / 30
BEAMing ctDNA:
KRAS G12 0,688%
KRAS Q61 0,114%
NRAS Q61 23,4%
Jan 2016
Diagnosis: ADK CRC
With multiple hepatic lesions
Folfori+Panitumumab
Folfori+Aflibercept
Aug 2017
April 2018
BEAMing ctDNA:
KRAS G12 1,553%
KRAS Q61 0,233%
NRAS G13 0,128%
NRAS Q61 30,76%
BEAMing ctDNA:
KRAS G12 0,11%
KRAS Q61 0,3%
May 2018
Exitus
PD
PD
Amplicon-seq:
ABL1 Y257N 7%
APC T1487fs 36%
VHIO_UMI panel ctDNA:
NRAS Q61L
14,53%
Pathogenic
NRAS Q61K 13,79% Pathogenic
NRAS Q61H 0,99% Pathogenic
NRAS G13R 0,4%
Pathogenic
KRAS Q61L 0,93% Pathogenic
KRAS G12V 2,5%
Pathogenic
APC Q1041* 4,72% Pathogenic
APC T1487fs 73,16%
Pathogenic
TP53 S96fs
72,73% Pathogenic
TP53 P72R
13,8% Bening
ERBB3 D112N 1,05%
VUS
BRCA2 S263R 1,05% Bening
KIT K86N 0,42% VUS
ABL1 gene is not present in the VHIO_UMI panel
4,4 ng/ul
ctDNA NGS shows higher complexity or RAS clones
and a more complete mutational landscape, including
other emergent clones and drivers
In collaboration with E. Élez
0,28 ng/ul
5,56 ng/ul
Intratumor
heterogeneity
Targeted
therapies
Clonality
mCRC: APC, KRAS vs
BRAF, PIK3CA
Lung: EGFR indel 19 vs
T790M vs C797S
Selection
mCRC: anti-EGFR, RAS
clones
Lung: EGFR T790M
Real world data_ Monitoring mCRC